Basiliximab versus ATG/ALG induction in pediatric renal transplants: comparison of herpes virus profile and rejection rates.
Acott
P D
PD
Department of Pediatrics, Dalhousie University, Halifax, Nova Scotia, Canada.
Lawen
J
J
Lee
S
S
Crocker
J F
JF
D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D000961:Antilymphocyte Serum / Q000009:adverse effects / Q000627:therapeutic use*; D000077552:Basiliximab; D002648:Child; D003586:Cytomegalovirus Infections / Q000453:epidemiology; D020031:Epstein-Barr Virus Infections / Q000453:epidemiology; D006084:Graft Rejection / Q000453:epidemiology*; D006566:Herpesviridae Infections / Q000453:epidemiology*; D015654:Herpesvirus 6, Human; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D016030:Kidney Transplantation / Q000276:immunology* / Q000473:pathology / Q000502:physiology; D007683:Kidney Tubular Necrosis, Acute / Q000517:prevention & control; D011183:Postoperative Complications / Q000145:classification / Q000453:epidemiology*; D011993:Recombinant Fusion Proteins
D000911:Antibodies, Monoclonal; D000961:Antilymphocyte Serum; D007166:Immunosuppressive Agents; D011993:Recombinant Fusion Proteins; D000077552:Basiliximab